Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS 3-Year EPS without NRI Growth Rate Related Terms
IST:ONCSM vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Oncosem Onkolojik Sistemlernayi ve Ticaret AS's 3-Year EPS without NRI Growth Rate falls into.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 0.00% mean?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a 3-Year EPS without NRI Growth Rate of 0.00% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. According to the industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #999999 out of 658 companies in the Medical Devices & Instruments industry.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's 3-Year EPS without NRI Growth Rate too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current 3-Year EPS without NRI Growth Rate is 0.00%. Based on the distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #999999 out of 658 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #999999 out of 658 companies for 3-Year EPS without NRI Growth Rate. This places Oncosem Onkolojik Sistemlernayi ve Ticaret AS in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.15, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current 3-Year EPS without NRI Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Fairly Valued. The stock's GF Value™ is ₺260.15, compared to a current price of ₺263.25 — trading 1.2% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 0.00%. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current 3-Year EPS without NRI Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺263.25 is trading 1.2% above its estimated GF Value™ of ₺260.15.
GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Fairly Valued.
Key valuation signals for IST:ONCSM:
3-Year EPS without NRI Growth Rate: 0.00%
GF Value™: ₺260.15 vs. price of ₺263.25 (1.2% above fair value)
No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ONCSM has been successfully added to your 
